CURAPOD, a Made-in-India, non-invasive pain management device backed by Litemed, has raised INR 20 crore in its Pre-Series A funding round, led by V3 Ventures. The round also included participation from 3i Partners and Ideaspring Capital.
The company plans to use the funding to speed up product development and improve its mobile app. It will also invest in branding and marketing and grow its direct-to-consumer sales by launching on more online marketplaces.
In addition, CURAPOD aims to build stronger partnerships with gyms, physiotherapy clinics, and sports medicine centres, while increasing its manufacturing capacity and sales operations.
A portion of the funding will support international expansion, starting with European markets. This includes meeting regulatory requirements, strengthening clinical validation, and building a local presence in those regions.
Arjun Vaidya, Co-founder and Managing Partner, V3 Ventures, said, “Pain is a chronic problem across age groups and demographics that people don’t do much about. CURAPOD is building a differentiated solution in this massive category. What we liked best is that it’s world-class, evidence-based technology from india. The ability to deliver measurable pain relief with strong clinical validation positions the company well for scale in India and even across international markets. I see this as the Whoop/Ultrahuman for pain and that’s what excites me.”
Subodh Toprani, Partner at 3I Partners, said, “CURAPOD’s wearable device brings clinically proven photobiomodulation therapy to customers in a simple, accessible format. Its strong evidence base, regulatory readiness and measurable results set it apart and the recent funding provides the resources to expand clinical reach and deepen adoption.”
Surya Maguluri, Founder & Chief Technology Officer, CURAPOD, backed by Litemed India Private Limited, said, “CURAPOD was developed to bridge the gap between conventional pain management and modern, non-invasive care. This funding supports the next phase of growth by enabling deeper clinical engagement, continued innovation, and broader access to personalised pain management solutions.”
Sri Velliyur, Co-founder & CEO, CURAPOD, backed by Litemed India Private Limited, said, “This funding marks a significant milestone in CURAPOD’s journey. Building on the strong momentum of the last 12 months, we are now focused on scaling pan-India and establishing CURAPOD as the go-to solution for everyday pain management. The capital will power expansion across manufacturing, supply chain, branding and marketing, key talent acquisition, and accelerated growth through D2C and marketplace channels.”
Naganand Doraswamy, Managing Partner, Ideaspring Capital, said, “CURAPOD is redefining how musculoskeletal pain is treated by bringing clinically proven photobiomodulation therapy into a wearable, user-friendly device. Ideaspring has been a proud backer of Litemed from its inception, and we believe the journey has just started as the company builds a wide portfolio of light-therapy–based pain relief devices for the future.”
Founded in 2022 by Sri Velliyur and Surya Maguluri, CURAPOD makes wearable, non-invasive devices that help manage muscle and joint pain.
The device uses light-based therapy to help relieve pain from back, neck, and knee issues, joint problems, muscle stiffness, and sports injuries.
CURAPOD’s device is FDA-registered and can help treat over 30 muscle and joint conditions. It offers a drug-free way to manage pain and follows a clinician-led approach, while continuing to expand its presence across India.
Read More- VinFast Enters Indonesia’s E-Scooter Market Through Strategic Dealer Partnerships
